tetano
Editor, Senior Moderator
Nat Commun
. 2024 Aug 6;15(1):6660.
doi: 10.1038/s41467-024-50802-2. Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial
Qianqian Xin[SUP] #[/SUP][SUP] 1 [/SUP], Kaiqin Wang[SUP] #[/SUP][SUP] 2 [/SUP], Teck-Hock Toh[SUP] 3 [/SUP], Yue Yuan[SUP] 1 [/SUP], Xing Meng[SUP] 4 [/SUP], Zhiwei Jiang[SUP] 5 [/SUP], Hengming Zhang[SUP] 4 [/SUP], Jinye Yang[SUP] 1 [/SUP], Huijie Yang[SUP] 6 [/SUP], Gang Zeng[SUP] 7 [/SUP]
Affiliations
Safe and effective vaccines against COVID-19 for children and adolescents are needed. This international multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial assessed the efficacy, immunogenicity, and safety of CoronaVac® in children and adolescents (NCT04992260). The study was carried out in Chile, South Africa, Malaysia, and the Philippines. The enrollment ran from September 10, 2021 to March 25, 2022. For efficacy assessment, the median follow-up duration from 14 days after the second dose was 169 days. A total of 11,349 subjects were enrolled. Two 3-μg injections of CoronaVac® or placebo were given 28 days apart. The primary endpoint was the efficacy of the CoronaVac®. The secondary endpoints were the immunogenicity and safety. The vaccine efficacy was 21.02% (95% CI: 1.65, 36.67). The level of neutralizing antibody in the vaccine group was significantly higher than that in the placebo group (GMT: 390.80 vs. 62.20, P <0.0001). Most adverse reactions were mild or moderate. All the severe adverse events were determined to be unrelated to the investigational products. In conclusion, in the Omicron-dominate period, a two-dose schedule of 3 μg CoronaVac® was found to be safe and immunogenic, and showed potential against symptomatic COVID-19 in healthy children and adolescents.
. 2024 Aug 6;15(1):6660.
doi: 10.1038/s41467-024-50802-2. Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial
Qianqian Xin[SUP] #[/SUP][SUP] 1 [/SUP], Kaiqin Wang[SUP] #[/SUP][SUP] 2 [/SUP], Teck-Hock Toh[SUP] 3 [/SUP], Yue Yuan[SUP] 1 [/SUP], Xing Meng[SUP] 4 [/SUP], Zhiwei Jiang[SUP] 5 [/SUP], Hengming Zhang[SUP] 4 [/SUP], Jinye Yang[SUP] 1 [/SUP], Huijie Yang[SUP] 6 [/SUP], Gang Zeng[SUP] 7 [/SUP]
Affiliations
- PMID: 39107270
- PMCID: PMC11303790
- DOI: 10.1038/s41467-024-50802-2
Safe and effective vaccines against COVID-19 for children and adolescents are needed. This international multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial assessed the efficacy, immunogenicity, and safety of CoronaVac® in children and adolescents (NCT04992260). The study was carried out in Chile, South Africa, Malaysia, and the Philippines. The enrollment ran from September 10, 2021 to March 25, 2022. For efficacy assessment, the median follow-up duration from 14 days after the second dose was 169 days. A total of 11,349 subjects were enrolled. Two 3-μg injections of CoronaVac® or placebo were given 28 days apart. The primary endpoint was the efficacy of the CoronaVac®. The secondary endpoints were the immunogenicity and safety. The vaccine efficacy was 21.02% (95% CI: 1.65, 36.67). The level of neutralizing antibody in the vaccine group was significantly higher than that in the placebo group (GMT: 390.80 vs. 62.20, P <0.0001). Most adverse reactions were mild or moderate. All the severe adverse events were determined to be unrelated to the investigational products. In conclusion, in the Omicron-dominate period, a two-dose schedule of 3 μg CoronaVac® was found to be safe and immunogenic, and showed potential against symptomatic COVID-19 in healthy children and adolescents.